Investigational Drug Fails As Standalone Mesothelioma Treatment, AstraZeneca Says
In its release, AstraZeneca said Tremelimumab remains a key component in combination treatments for various types of tumors.
Tremelimumab is currently being studied in combination with another AstraZeneca drug, Durvalumab, as a treatment for numerous tumors, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers, the company said.
Tremelimumab is a selective antibody drug...
To view the full article, register now.